These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 9345362)

  • 1. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
    Friedman RL; Eisenkop SM; Wang HJ
    Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
    Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
    Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-look laparotomy in carcinoma of the fallopian tube.
    Barakat RR; Rubin SC; Saigo PE; Lewis JL; Jones WB; Curtin JP
    Obstet Gynecol; 1993 Nov; 82(5):748-51. PubMed ID: 8414320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
    Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
    Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
    Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
    Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
    Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the role of second-look surgery in ovarian cancer.
    Chambers SK; Chambers JT; Kohorn EI; Lawrence R; Schwartz PE
    Obstet Gynecol; 1988 Sep; 72(3 Pt 1):404-8. PubMed ID: 3405557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
    Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
    Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma].
    Sevelda P; Barrada M; Vavra N; Denison U; Schmidl S; Genger H; Salzer H
    Wien Klin Wochenschr; 1990 Aug; 102(15):441-3. PubMed ID: 2402929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
    Landoni F; Pellegrino A; Cormio G; Milani R; Maggioni A; Mangioni C
    Acta Obstet Gynecol Scand; 1998 Feb; 77(2):233-7. PubMed ID: 9512334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.